A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
This study will be a 2-period study conducted with 14 healthy male or female subjects. Subjects will be administered surufatinib alone in Period 1 and in combination with itraconazole in Period 2.

Detailed Description
-----------------
This study will be a single center, open label, fixed-sequence crossover, 2-period study conducted with 14 healthy male or female subjects. Subjects will be administered surufatinib alone in Period 1 and in combination with itraconazole in Period 2. PK samples will be collected through out both study periods.Subjects will be confined in the clinic from check-in on Day -1 through the end-of study visit on Day 15.

Official Title
-----------------
A Phase 1, Two Period Fixed-sequence Crossover Study to Assess the Effects of Itraconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics of Surufatinib in Healthy Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Surufatinib
* Drug: Itraconazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-smoking, healthy male or female between the ages of 18 and 55 years old (inclusive). Body mass index (BMI) > 18 and ≤ 29 kg/m2. Females must be of non-childbearing potential, or of childbearing potential and agree to use a medically acceptable method of contraception. Males who have not had a successful vasectomy and are partners of women of childbearing potential must use, or their partners must use, a highly effective method of contraception starting for at least one menstrual cycle prior to and throughout the entire study period, and for 2 weeks after the last dose of study drug. Those with partners using hormonal contraceptives must also use an additional approved method of contraception. No sperm donation is allowed during the study period and for 90 days after study drug discontinuation. Exclusion Criteria: Evidence of clinically significant cardiovascular, hepatic, GI, renal, respiratory, endocrine, hematological, neurological, or psychiatric disease or abnormalities or had a known history of any GI surgery or cholecystectomy. Clinically significant illness within 8 weeks or had a clinically significant infection within 4 weeks prior to the first dose. Clinically significant deviation from normal in the physical examination, vital signs, or clinical laboratory determinations. Systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg. The subject has a clinically significant ECG abnormality, or had a family history of prolonged QTc syndrome or sudden death. A history of smoking or use of nicotine-containing substances within the previous 2 months. A history of drug or alcohol misuse in the previous 6 months. Has been diagnosed with acquired immune deficiency syndrome (AIDS) or are positive for human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV). Has participated in a clinical trial of other drug before screening, and the time since the last use of other study drug is less than 5 times the half-life or 4 weeks, whichever is longer, or the subject is currently enrolled in another clinical trial. Has received blood or blood products within 4 weeks, or donated blood or blood products within 8 weeks. Has used any over-the-counter (OTC) medications or prescription drugs within 2 weeks.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment Crossover Arm<br>All patients will receive a single dose of surufatinib on day 1 in period 1, and a both itraconazole and single dose of surufatinib in period 2 | Drug: Surufatinib<br>* Surufatinib: 200 mg as single dose on Days 1 and 9<br>Drug: Itraconazole<br>* Itraconazole: 200 mg BID on Day 5, then 200 mg QD on Days 6 to 14<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUC (0-t) of Surufatinib | Pharmacokinetics of surufatinib by assessment of area under the plasma concentration time curve from zero to the last measurable concentration | Up to Day 15 | 
| AUC of Surufatinib | Pharmacokinetics of surufatinib by assessment of area under the plasma concentration curve from zero extrapolated to infinity | Up to Day 15 | 
| Cmax of Surufatinib | Pharmacokinetics of Surufatinib by assessment of maximum plasma Surufatinib concentration | Up to Day 15 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with treatment emergent adverse events as assessed by CTCAE v5.0 | To evaluate the safety, in healthy subjects, of a single dose of surufatinib administered with and without food | Up to Day 15 |